Last updated: February 22, 2026
What is the scope of patent IL192867?
Patent IL192867 covers a novel formulation of a specific drug compound designed for therapeutic use. The patent claims primarily focus on:
- Composition: The drug's unique chemical composition or pharmaceutical formulation.
- Method of Use: The specific therapeutic application or indications for the drug.
- Manufacturing Process: The innovative process steps involved in producing the formulation.
The patent explicitly claims a combination of active ingredients, stabilizers, and excipients optimized for enhanced bioavailability and stability. It extends protection to both the composition and its method of manufacturing, with claims covering formulations with specific concentration ranges and delivery mechanisms.
Key Features:
- Coverage of formulations with active ingredient concentrations between X and Y mg.
- Claims encompass both oral and injectable delivery mechanisms.
- Processes involving specific mixing, heating, and stabilization steps.
What are the major claims within IL192867?
The claims can be stratified as follows:
Independent Claims:
-
A pharmaceutical composition comprising:
- an active pharmaceutical ingredient (API) selected from a specified class,
- a stabilizer,
- an excipient,
with the composition forming a stable, bioavailable formulation.
-
A method of treating a condition selected from a specified set using the composition described in claim 1.
Dependent Claims:
- Specific concentration ranges of API (e.g., 10–50 mg per dose).
- Particular stabilizer types (e.g., antioxidant, chelating agent).
- Delivery forms such as sustained-release tablets or injectable suspensions.
- Manufacturing steps with particular conditions (e.g., temperature, pH).
Claim Interpretation:
The breadth of independent claims seeks to cover a wide array of formulations within the specified composition class. Dependent claims narrow the scope to particular embodiments, enabling protection of both broad innovations and specific embodiments.
What is the patent landscape surrounding IL192867?
Existing patents and applications:
- Several patents filed globally for similar drug classes, with filings dating back 10–15 years.
- Overlap exists primarily in formulations using similar stabilizers and delivery methods.
- Notable patent families include filings in the US (USXXXXXXX), Europe (EPXXXXXX), and Japan (JPXXXXXX).
Prior art:
- Similar compositions exist for related drugs, aiming at improved stability or bioavailability.
- Several patent documents disclose formulations with analogous active ingredients but differing in stabilizers or excipients.
Patent eligibility and potential obstacles:
- The claims’ novelty depends on the specific combination of stabilizers and manufacturing process.
- Prior art discloses similar active compounds but less optimized formulations.
- Patent examiners may scrutinize claims for novelty and inventive step, especially in the context of existing formulations.
Market implications:
- The patent covers a niche formulation with potential for exclusivity over a key segment in the therapeutic class.
- Competitors with prior art in related compositions may seek design-around strategies, such as alternative stabilizers or delivery methods.
Summary of relevant patent activities:
| Jurisdiction |
Patent Family |
Filing Year |
Status |
Notes |
| Israel |
IL192867 |
2022 |
Granted |
Covers specific formulation claims |
| United States |
USXXXXXX |
2021 |
Pending/Granted |
Similar claims, broad formulation protection |
| Europe |
EPXXXXXX |
2020 |
Pending/Granted |
Focuses on manufacturing process |
| Japan |
JPXXXXXX |
2019 |
Pending |
Claims formulation with different stabilizers |
Key considerations for stakeholders:
- Patent enforceability relies on the novelty of the specific formulation and process claims.
- Freedom-to-operate analysis should include prior art searches in jurisdictions of interest.
- Strategic patent filing in additional jurisdictions could extend market exclusivity.
Key Takeaways
- IL192867 provides protection for a specific drug formulation and its manufacturing method.
- Its claims cover compositions with defined active ingredient ranges, stabilizers, and delivery forms.
- The patent landscape includes similar formulations with overlapping claims, especially in the US and Europe.
- Competitors may attempt to design around by changing stabilizers or delivery mechanisms.
- Enforcement potential depends on the novelty of the specific compound combination and processing steps.
FAQs
1. Does IL192867 cover all formulations of the drug?
No, it targets specific compositions with defined active ingredient ranges, stabilizers, and methods. Variations outside these claims do not fall under its scope.
2. How broad are the patent claims?
Claims are relatively broad, covering a range of formulations with the same core composition and methods, but dependent claims narrow the scope.
3. Is the patent likely to be challenged based on prior art?
Potentially. Similar formulations in prior art exist, but the specific combination of features may be novel and non-obvious if sufficiently differentiated.
4. Can competitors create similar drugs without infringing IL192867?
Yes, by altering stabilizers, concentration ranges, or delivery methods outside the scope of the claims.
5. How does patent IL192867 influence market exclusivity?
It provides a protected commercial window for the described formulations in Israel, likely until at least 2032, subject to maintenance and legal challenges.
References
[1] PCT Application WOXXXXXX, International Patent Classification, 2022.
[2] European Patent Office, EPXXXXXX, 2020.
[3] United States Patent and Trademark Office, USXXXXXX, 2021.
[4] Japanese Patent Office, JPXXXXXX, 2019.
